This Article Figures Only Full Text Full Text (PDF) Online Appendix View Related Story on Cardiosmart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Groenveld, H. F. Articles by van der Meer, P. Search for Related Content PubMed Articles by Groenveld, H. F. Articles by van der Meer, P. Related Collections Related Article

CLINICAL RESEARCH: HEART FAILURE

Anemia and Mortality in Heart Failure Patients

A Systematic Review and Meta-Analysis

Hessel F. Groenveld, MD^_*, James L. Januzzi, MD, FACC, Kevin Damman, MD^_*, Jan van Wijngaarden, MD, PhD, Hans L. Hillege, MD, PhD^_*, Dirk J. van Veldhuisen, MD, PhD, FACC^_* and Peter van der Meer, MD, PhD^,_*

^_* Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands
Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
Department of Cardiology, Deventer Hospital, Deventer, the Netherlands

Manuscript received February 19, 2008; revised manuscript received April 23, 2008, accepted April 28, 2008.

^_* Reprint requests and correspondence: Dr. Peter van der Meer, Cardiovascular Research Center, Massachusetts General Hospital, Charles River Plaza, 185 Cambridge Street, Boston, Massachusetts 02114 (Email: pvandermeer{at}partners.org).

Objectives: The aim of this study was to assess the effect of anemia on mortality in chronic heart failure (CHF).

Background: Anemia is frequently observed in patients with CHF, and evidence suggests that anemia might be associated with an increased mortality.

Methods: A systematic literature search in MEDLINE (through November 2007) for English language articles was performed. In addition, a manual search was performed. We included cohort studies and retrospective secondary analyses of randomized controlled trials whose primary objective was to analyze the association between anemia and mortality in CHF. Of a total of 1,327 initial studies, we included 34 studies, comprising 153,180 patients. Information on study design, patient characteristics, outcome, and potential confounders were extracted.

Results: Anemia was defined by criteria used in the original articles. Of the 153,180 CHF patients, 37.2% were anemic. After a minimal follow-up of 6 months, 46.8% of anemic patients died compared with 29.5% of nonanemic patients. Crude mortality risk of anemia was odds ratio 1.96 (95% confidence interval: 1.74 to 2.21, p < 0.001). Lower baseline hemoglobin values were associated with increased crude mortality rates (r = –0.396, p = 0.025). Adjusted hazard ratios showed an increased adjusted risk for anemia (hazard ratio 1.46 [95% confidence interval: 1.26 to 1.69, p < 0.001]). Subgroup analysis showed no significant difference between mortality risk of anemia in diastolic or systolic CHF.

Conclusions: Anemia is associated with an increased risk of mortality in both systolic and diastolic CHF. Anemia should, therefore, be considered as a useful prognosticator, and therapeutic strategies aimed to increase hemoglobin levels in CHF should be investigated.

Key Words: heart failure • anemia • prognosis

Abbreviations and Acronyms   CHF = chronic heart failure   CI = confidence interval   EPO = erythropoietin   ESP = erythropoiesis-stimulating protein   Hb = hemoglobin   HR = hazard ratio   Ht = hematocrit   OR = odds ratio   WHO = World Health Organization

Related Article

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A31-A32. [Full Text] [PDF]

This article has been cited by other articles:

				G. W. Dec Anemia and Iron Deficiency -- New Therapeutic Targets in Heart Failure? N. Engl. J. Med., November 17, 2009; (2009) NEJMe0910313v1. [Full Text] [PDF]

				P. van der Meer and D. J van Veldhuisen Anaemia and renal dysfunction in chronic heart failure Heart, November 1, 2009; 95(21): 1808 - 1812. [Full Text] [PDF]

				M. Klapholz, W. T. Abraham, J. K. Ghali, P. Ponikowski, S. D. Anker, B. Knusel, Y. Sun, S. M. Wasserman, and D. J. van Veldhuisen The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure Eur J Heart Fail, November 1, 2009; 11(11): 1071 - 1077. [Abstract] [Full Text] [PDF]

				A. Cohen-Solal, D. Kotecha, D. J van Veldhuisen, D. Babalis, M. Bohm, A. J. Coats, M. Roughton, P. Poole-Wilson, L. Tavazzi, M. Flather, et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial Eur J Heart Fail, September 1, 2009; 11(9): 872 - 880. [Abstract] [Full Text] [PDF]

				D. A. Pascual-Figal, J. C. Bonaque, B. Redondo, C. Caro, S. Manzano-Fernandez, J. Sanchez-Mas, I. P. Garrido, and M. Valdes Red blood cell distribution width predicts long-term outcome regardless of anaemia status in acute heart failure patients Eur J Heart Fail, September 1, 2009; 11(9): 840 - 846. [Abstract] [Full Text] [PDF]

				A. Besarab, W. H. Horl, and D. Silverberg Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome Oncologist, September 1, 2009; 14(suppl_1): 22 - 33. [Abstract] [Full Text] [PDF]

				P van der Meer, H F Groenveld, J L Januzzi Jr, and D J van Veldhuisen Erythropoietin treatment in patients with chronic heart failure: a meta-analysis Heart, August 15, 2009; 95(16): 1309 - 1314. [Abstract] [Full Text] [PDF]

				J. J.V. McMurray, I. S. Anand, R. Diaz, A. P. Maggioni, C. O'Connor, M. A. Pfeffer, K. R. Polu, S. D. Solomon, Y. Sun, K. Swedberg, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial Eur J Heart Fail, August 1, 2009; 11(8): 795 - 801. [Abstract] [Full Text] [PDF]

				J. L. Amato Jr., J. L. Amato Sr., J. K. Ghali, H. Tomoda, G. Schillaci, G. Pucci, M. Pirro, B. M. Massie, P. E. Carson, and the I-PRESERVE Investigators Irbesartan for Heart Failure with Preserved Ejection Fraction N. Engl. J. Med., March 19, 2009; 360(12): 1256 - 1259. [Full Text] [PDF]

				E. Gao and W. J. Koch Is erythropoietin behind maladaptive anemic heart failure? Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H559 - H560. [Full Text] [PDF]

				J. McMurray, M. Petrie, K. Swedberg, M. Komajda, S. Anker, and R. Gardner CHAPTER 23 Heart Failure ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				P. van der Meer, J. L. Januzzi, and D. J. van Veldhuisen Erythropoietin, haemoglobin, heart failure, and mortality: reply Eur. Heart J., November 1, 2008; 29(21): 2695 - 2696. [Full Text] [PDF]